As you well know, developed markets simultaneously face the issues of aging populations and faltering economies. As these issues put pressure on healthcare spending, each country must find ways to lower healthcare and pharmaceutical costs. At the same time, safety and efficacy criteria are becoming stricter globally as the development process for new drugs becomes even more challenging.
With the changing business environment in mind, Daiichi Sankyo is taking variety of initiatives to further strengthen our core business while developing and growing our business for the future.
Business plan
1. Strengthen and expand innovative pharmaceutical business (new drugs)
2. Expand business base for established pharmaceuticals (generics, etc.), vaccines and OTC pharmaceuticals
For the development of our innovative pharmaceutical business which has a long investment payback period, sales expansion and improvement in profitability is crucial to ensure ROI and secure R&D investments.
In order to achieve these goals, we will work to maximize the value of existing products (through lifecycle management by supplemental indications, etc.) while expanding business in high growth developing markets such as India and China. We will also focus on enhancing our R&D pipeline through concentration and reinforcement of our core therapeutic areas, to ensure continuous corporate growth.
We expect our established pharmaceuticals, vaccines and OTC pharmaceuticals to contribute to our long-term success, and are now expanding their business base.
2011 is the second year of our Second Mid-term Business Management Plan. We will continue to improve our initiatives towards our 2012 targets and long-term growth, and to realize our corporate mission, "to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and through the provision of pharmaceuticals addressing diverse medical needs."
I look forward to the continued understanding and support of all our stakeholders.
Joji Nakayama
Representative Director, President and CEO
